Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

$Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP$

Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP

by van den Berg, Anke , Morschhauser, Franck , Kersten, Marie José , Driessen, Julia , Gastinne, Thomas , Amorim, Sandy , Zwezerijnen, Gerben J. C , de Vet, Henrica C. W , Lugtenburg, Pieternella J , Visser, Lydia , Liu, Roberto D. K , Tonino, Sanne H , Boellaard, Ronald , Nijland, Marcel , Hutchings, Martin , Drees, Esther E. E , Valkema, Roelf , de Jong, Daphne , Plattel, Wouter J , Arens, Anne I. J , Diepstra, Arjan , Zijlstra, Josée M

in Autografts / Biopsy / Calciferol / Clinical trials / Hodgkin's lymphoma / Immunohistochemistry / Immunotherapy / L-Lactate dehydrogenase / Lactate dehydrogenase / Lactic acid / Lymphoma / Medical prognosis / Monoclonal antibodies / Parameters / Patients / Positron emission / Reed-Sternberg cells / Risk / Staining / Stem cell transplantation / Stem cells / Survival / Targeted cancer therapy / Toxicity / Transplantation / Transplants & implants / Tumors / Vitamin D

2022

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP

2022

Confirm

Do you wish to request the book?

$Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP$

Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP

2022

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

$Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP$

Journal Article

Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP

van den Berg, Anke,

Morschhauser, Franck,

Kersten, Marie José,

Driessen, Julia,

Gastinne, Thomas,

Amorim, Sandy,

Zwezerijnen, Gerben J. C,

de Vet, Henrica C. W,

Lugtenburg, Pieternella J,

Visser, Lydia,

Liu, Roberto D. K,

Tonino, Sanne H,

Boellaard, Ronald,

Nijland, Marcel,

Hutchings, Martin,

Drees, Esther E. E,

Valkema, Roelf,

de Jong, Daphne,

Plattel, Wouter J,

Arens, Anne I. J,

Diepstra, Arjan,

Zijlstra, Josée M

2022

Overview

Risk-stratified treatment strategies have the potential to increase survival and lower toxicity in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients. This study investigated the prognostic value of serum (s)TARC, vitamin D and lactate dehydrogenase (LDH), TARC immunohistochemistry and quantitative PET parameters in 65 R/R cHL patients who were treated with brentuximab vedotin (BV) and DHAP followed by autologous stem-cell transplantation (ASCT) within the Transplant BRaVE study (NCT02280993). At a median follow-up of 40 months, the 3-year progression free survival (PFS) was 77% (95% CI: 67–88%) and the overall survival was 95% (90–100%). Significant adverse prognostic markers for progression were weak/negative TARC staining of Hodgkin Reed-Sternberg cells in the baseline biopsy, and a high standard uptake value (SUV)mean or SUVpeak on the baseline PET scan. After one cycle of BV-DHAP, sTARC levels were strongly associated with the risk of progression using a cutoff of 500 pg/ml. On the pre-ASCT PET scan, SUVpeak was highly prognostic for progression post-ASCT. Vitamin D, LDH and metabolic tumor volume had low prognostic value. In conclusion, we established the prognostic impact of sTARC, TARC staining, and quantitative PET parameters for R/R cHL, allowing the use of these parameters in prospective risk-stratified clinical trials. Trial registration: NCT02280993.

Share this book

Add to My Shelf

Publisher

Nature Publishing Group

Subject

/ Biopsy

/ Immunohistochemistry

/ Immunotherapy